Core Insights - InSilico Medicine has become the first artificial intelligence biopharmaceutical company to list on the Hong Kong Stock Exchange under the main board listing rule 8.05, raising a total of HKD 2.277 billion, making it the highest fundraising biopharmaceutical IPO in Hong Kong for the year [1] - The IPO was co-sponsored by Morgan Stanley, CICC, and GF Securities, with a total issuance of 94.6905 million shares, of which 10% was allocated for public offering in Hong Kong, achieving an oversubscription rate of approximately 1,427.37 times, locking in subscription funds exceeding HKD 32.8349 billion [1] - The company plans to increase investment in its AI platform and innovative pipeline to accelerate the entry of more globally differentiated innovative projects into clinical trials [1] Company Collaborations - InSilico Medicine has established software licensing collaborations with 13 of the top 20 global pharmaceutical companies [2] - The company has also secured three pipeline licensing collaborations with Exelixis and Menarini, with a total collaboration potential of up to USD 2.1 billion, and has engaged in joint research collaborations with renowned pharmaceutical companies such as Fosun Pharma, Sanofi, and Eli Lilly [2] Key Asset - The core asset of InSilico Medicine is Rentosertib, a drug for treating idiopathic pulmonary fibrosis, which is the industry's most advanced first-in-class AI drug, having completed Phase IIa clinical trials domestically, marking a significant milestone in AI-driven drug development [1]
AI制药企业英矽智能挂牌港交所